65,457 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Deutsche Bank AG

Deutsche Bank AG bought a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 65,457 shares of the company’s stock, valued at approximately $4,120,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. RTW Investments LP grew its stake in Tarsus Pharmaceuticals by 5.0% during the fourth quarter. RTW Investments LP now owns 3,335,320 shares of the company’s stock valued at $273,096,000 after acquiring an additional 157,884 shares in the last quarter. Deep Track Capital LP increased its holdings in shares of Tarsus Pharmaceuticals by 71.4% in the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after purchasing an additional 1,250,000 shares during the period. Vanguard Group Inc. raised its position in shares of Tarsus Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock worth $196,476,000 after buying an additional 127,470 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Tarsus Pharmaceuticals by 16.1% in the first quarter. Janus Henderson Group PLC now owns 2,240,963 shares of the company’s stock worth $157,223,000 after buying an additional 310,638 shares in the last quarter. Finally, Morgan Stanley raised its position in shares of Tarsus Pharmaceuticals by 6.7% in the fourth quarter. Morgan Stanley now owns 2,040,742 shares of the company’s stock worth $167,096,000 after buying an additional 128,340 shares in the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total transaction of $615,500.00. Following the completion of the transaction, the chief executive officer owned 847,991 shares of the company’s stock, valued at approximately $52,193,846.05. This trade represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Goodrich sold 2,954 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $62.08, for a total transaction of $183,384.32. Following the transaction, the director owned 2,233 shares of the company’s stock, valued at $138,624.64. The trade was a 56.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 39,850 shares of company stock worth $2,452,821. Corporate insiders own 9.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Mizuho lowered their price target on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Guggenheim cut their price target on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Tuesday, July 21st. Finally, Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.50.

Tarsus Pharmaceuticals Price Performance

Shares of Tarsus Pharmaceuticals stock opened at $71.45 on Wednesday. The company has a quick ratio of 3.17, a current ratio of 3.20 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $85.25. The company has a market cap of $3.14 billion, a PE ratio of -65.55 and a beta of 0.53. The business has a 50 day moving average of $63.88 and a 200 day moving average of $65.18.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The company had revenue of $173.91 million during the quarter, compared to analysts’ expectations of $169.65 million. As a group, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.